RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 107 filers reported holding RIGEL PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $216,000 | -16.3% | 200,000 | 0.0% | 0.03% | -10.8% |
| Q2 2023 | $258,000 | -2.3% | 200,000 | 0.0% | 0.04% | -9.8% |
| Q1 2023 | $264,000 | -12.0% | 200,000 | 0.0% | 0.04% | -16.3% |
| Q4 2022 | $300,000 | +27.1% | 200,000 | 0.0% | 0.05% | +22.5% |
| Q3 2022 | $236,000 | +4.4% | 200,000 | 0.0% | 0.04% | +8.1% |
| Q2 2022 | $226,000 | -62.2% | 200,000 | 0.0% | 0.04% | -54.3% |
| Q1 2022 | $598,000 | +12.8% | 200,000 | 0.0% | 0.08% | +20.9% |
| Q4 2021 | $530,000 | -27.0% | 200,000 | 0.0% | 0.07% | -32.3% |
| Q3 2021 | $726,000 | -16.4% | 200,000 | 0.0% | 0.10% | -13.9% |
| Q2 2021 | $868,000 | +26.9% | 200,000 | 0.0% | 0.12% | +18.6% |
| Q1 2021 | $684,000 | -2.3% | 200,000 | 0.0% | 0.10% | -10.2% |
| Q4 2020 | $700,000 | +45.8% | 200,000 | 0.0% | 0.11% | +25.6% |
| Q3 2020 | $480,000 | +31.1% | 200,000 | 0.0% | 0.09% | +24.6% |
| Q2 2020 | $366,000 | +17.3% | 200,000 | 0.0% | 0.07% | -2.8% |
| Q1 2020 | $312,000 | -27.1% | 200,000 | 0.0% | 0.07% | -2.7% |
| Q4 2019 | $428,000 | +14.4% | 200,000 | 0.0% | 0.07% | +7.4% |
| Q3 2019 | $374,000 | -28.4% | 200,000 | 0.0% | 0.07% | -27.7% |
| Q2 2019 | $522,000 | +1.6% | 200,000 | 0.0% | 0.09% | 0.0% |
| Q1 2019 | $514,000 | +11.7% | 200,000 | 0.0% | 0.09% | -2.1% |
| Q4 2018 | $460,000 | -20.4% | 200,000 | +11.1% | 0.10% | -2.0% |
| Q3 2018 | $578,000 | +85.9% | 180,000 | +63.6% | 0.10% | +75.0% |
| Q2 2018 | $311,000 | -41.4% | 110,000 | -26.7% | 0.06% | -41.1% |
| Q1 2018 | $531,000 | -8.8% | 150,000 | 0.0% | 0.10% | -5.9% |
| Q4 2017 | $582,000 | -21.0% | 150,000 | -48.3% | 0.10% | -24.6% |
| Q3 2017 | $737,000 | -23.9% | 290,000 | -18.3% | 0.13% | -26.8% |
| Q2 2017 | $969,000 | -17.5% | 355,000 | 0.0% | 0.18% | -17.9% |
| Q1 2017 | $1,175,000 | +39.1% | 355,000 | 0.0% | 0.22% | +32.7% |
| Q4 2016 | $845,000 | -35.1% | 355,000 | 0.0% | 0.17% | -37.8% |
| Q3 2016 | $1,303,000 | +129.0% | 355,000 | +39.2% | 0.27% | +123.1% |
| Q2 2016 | $569,000 | -11.8% | 255,000 | 0.0% | 0.12% | -11.7% |
| Q1 2016 | $645,000 | -16.6% | 255,000 | 0.0% | 0.14% | -13.8% |
| Q4 2015 | $773,000 | +22.7% | 255,000 | 0.0% | 0.16% | +16.9% |
| Q3 2015 | $630,000 | – | 255,000 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |